101 related articles for article (PubMed ID: 3701144)
1. [Significance of immunosuppressive acidic protein in the diagnosis and follow-up of patients with ovarian cancer, in particular as a marker for chemotherapeutic effects].
Shimizu Y; Akagaki E; Hirota K; Kono M; Miura S; Okudaira Y; Kurachi K
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Apr; 38(4):554-60. PubMed ID: 3701144
[TBL] [Abstract][Full Text] [Related]
2. [Immunosuppressive acidic protein in patients with gynecologic cancer].
Sawada M; Matsui Y; Okudaira Y; Shimizu Y; Takayama K
Nihon Sanka Fujinka Gakkai Zasshi; 1983 May; 35(5):605-11. PubMed ID: 6408203
[TBL] [Abstract][Full Text] [Related]
3. [Variations in the level of immunosuppressive acidic protein in patients with gynecologic tumors and pregnant women].
Sawada M; Okudaira Y; Matsui Y; Miyoshi Y; Takayama K; Shimizu Y; Miura S
Gan To Kagaku Ryoho; 1983 Aug; 10(8):1823-30. PubMed ID: 6882005
[TBL] [Abstract][Full Text] [Related]
4. [Studies on immunosuppressive acidic protein (IAP) in ovarian tumors].
Miyoshi T; Nishimura H; Hamai J; Yamada T; Tomoo Y; Kobayashi H; Yakushiji M; Kato T
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Jun; 37(6):923-9. PubMed ID: 2991397
[TBL] [Abstract][Full Text] [Related]
5. ["Immunosuppressive acidic protein" (IAP)--an improvement for tumor marker diagnosis in epithelial ovarian cancer?].
Sevelda P; Haider F; Spona J
Geburtshilfe Frauenheilkd; 1987 Jul; 47(7):452-5. PubMed ID: 3476335
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive acidic protein in patients with ovarian cancer.
Sawada M; Okudaira Y; Matsui Y; Shimizu Y
Cancer; 1983 Dec; 52(11):2081-5. PubMed ID: 6627216
[TBL] [Abstract][Full Text] [Related]
7. [Studies on the clinical significance of type III procollagen peptide in sera as a tumor marker in patients with ovarian tumors].
Mori T; Itoh E
Nihon Gan Chiryo Gakkai Shi; 1989 May; 24(5):974-89. PubMed ID: 2778385
[TBL] [Abstract][Full Text] [Related]
8. [Investigation of serum immunosuppresive acidic protein levels in gynecological tumor].
Zhang W; Wang P; Zhao Y
Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):194-6. PubMed ID: 11601039
[TBL] [Abstract][Full Text] [Related]
9. [Serum levels of immunosuppressive acidic protein in gynecological cancer].
Sato S; Wakisaka T; Hamazaki Y; Oikawa N; Toki T; Yamauchi R; Sakahira H; Tase T; Yajima A; Suzuki M
Gan No Rinsho; 1983 Jul; 29(8):897-9. PubMed ID: 6887522
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of immunosuppressive acidic protein (IAP), CA 125 and acute-phase proteins as parameters for ovarian cancer monitoring.
Koebl H; Tatra G; Bieglmayer C
Neoplasma; 1988; 35(2):215-20. PubMed ID: 3259680
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppressive acidic protein in patients with gynecologic cancer.
Sawada M; Okudaira Y; Matsui Y; Shimizu Y
Cancer; 1984 Aug; 54(4):652-6. PubMed ID: 6744202
[TBL] [Abstract][Full Text] [Related]
12. [Immunosuppressive acidic protein (IAP) in gynecologic malignant tumors and its relationship with other immunosuppressive substances and cell-mediated immunity].
Takada M
Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt):237-44. PubMed ID: 6881975
[TBL] [Abstract][Full Text] [Related]
13. [Significance of CA 125 antigen levels in patients with ovarian cancer].
Shimizu Y; Fujiwara H; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Okudaira Y
Gan To Kagaku Ryoho; 1986 Jan; 13(1):46-52. PubMed ID: 3455806
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of CA 125 assay system and its diagnostic significance in gynecologic tumors].
Shimizu Y; Akagaki E; Hirota K; Kono M; Miura S; Okudaira Y
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Dec; 37(12):2813-20. PubMed ID: 3866801
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous measurement of CA 125, CA 19-9, tissue polypeptide antigen, and immunosuppressive acidic protein to predict recurrence of ovarian cancer.
Kamiya N; Mizuno K; Kawai M; Kano T; Furuhashi Y; Tomoda Y
Obstet Gynecol; 1990 Sep; 76(3 Pt 1):417-21. PubMed ID: 2381619
[TBL] [Abstract][Full Text] [Related]
16. Serum immunosuppressive acidic protein reflects systemic deterioration of colorectal cancer patient condition.
Toiyama Y; Miki C; Inoue Y; Okugawa Y; Koike Y; Watanabe H; Yokoe T; Hiro J; Ojima E; Tanaka K; Kusunoki M
J Surg Oncol; 2008 Apr; 97(5):404-8. PubMed ID: 18181167
[TBL] [Abstract][Full Text] [Related]
17. Significance of the O6-methylguanine-DNA methyltransferase and glutathione S-transferase activity in the sera of patients with malignant and benign ovarian tumors.
Akçay T; Dinçer Y; Alademir Z; Aydinli K; Arvas M; Demirkiran F; Kösebay D
Eur J Obstet Gynecol Reprod Biol; 2005 Mar; 119(1):108-13. PubMed ID: 15734094
[TBL] [Abstract][Full Text] [Related]
18. [Urine levels of immunosuppressive acidic protein in patients with or without cancer].
Hirayama T
Nihon Geka Gakkai Zasshi; 1985 Oct; 86(10):1379-87. PubMed ID: 4079895
[TBL] [Abstract][Full Text] [Related]
19. Prediction of clinical course and recurrence of human ovarian cancer by several serum tumor markers.
Kikuchi Y; Kita T; Iwano I; Kuki E; Oomori K; Kizawa I
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jan; 41(1):69-76. PubMed ID: 2926196
[TBL] [Abstract][Full Text] [Related]
20. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
